Zura Bio Ltd
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
ZURA$1.41+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the Six | ||||||
| · · Months Ended | ||||||
| · · June 30, | ||||||
| · 2024 · 2023 | ||||||
| Cash flows from operating activities · · · · | ||||||
| Net loss before redeemable noncontrolling interest | | $(18,076) | | $(43,820) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Research and development acquired license | | | — | | 27,381 | |
| Anti-dilution share issuance compensation | | | — | | | 2,186 |
| Share-based compensation expense | | | 5,335 | | 2,498 | |
| Change in fair value of note payable | | | — | | 2,244 | |
| Change in fair value of research and development license consideration liability | | | — | | 1,854 | |
| Change in fair value of private placement warrants | | | 1,374 | | 355 | |
| Depreciation and amortization | | | 1 | | — | |
| Foreign exchange transaction (gain)/loss | | | (25) | | 6 | |
| Changes in operating assets and liabilities: | | | | | | |
| Prepaid expenses and other current assets | | | 5 | | (321) | |
| Accounts payable and accrued expenses | | | (213) | | (813) | |
| Net cash used in operating activities | | | (11,599) | | (8,430) | |
| Cash flows from investing activities | | | | | | |
| Purchase of fixed assets | | | (17) | | | — |
| Purchase of research and development license | | | (5,000) | | | (5,750) |
| Net cash used in investing activities | | | (5,017) | | (5,750) | |
| Cash flows from financing activities | | | | | | |
| Proceeds from issuance of Ordinary Shares in connection with April 2024 Private Placement, net of $7.2 million of transaction costs | | | 55,223 | | | — |
| Proceeds from issuance of Pre-Funded Warrants in connection with April 2024 Private Placement | | | 50,030 | | — | |
| Proceeds from issuance of Ordinary Shares in connection with April 2023 Private Placement, net of $0.1 million of transaction costs | | | — | | | 63,846 |
| Proceeds from issuance of Class A Ordinary Shares upon Closing of Business Combination | | | — | | | 56,683 |
| Proceeds from issuance of Pre-Funded Warrants in connection with April 2023 Private Placement | | | — | | | 16,070 |
| Settlement of note payable | | | — | | | (10,000) |
| Payment of deferred transaction costs | | | — | | | (1,184) |
| Net cash provided by financing activities | | | 105,253 | | | 125,415 |
| Net increase in cash and cash equivalents | | | 88,637 | | | 111,235 |
| Cash and cash equivalents, beginning of period | | | 99,806 | | | 1,567 |
| Cash and cash equivalents, ending of period | | $188,443 | | $112,802 | ||
| | | | | | | |
| Supplemental Disclosure | | | | | | |
| Cash paid for taxes | | $— | | $— | ||
| Cash paid for interest | | $— | | $— | ||
| | | | | | | |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities | | | | | | |
| Conversion of Series A-1 convertible preferred shares for Class A Ordinary Shares | | $— | | $14,686 | ||
| Accrued 2023 Lilly License consideration | | $— | | $12,250 | ||
| Deemed dividend to redeemable noncontrolling interest | | $— | | $10,875 | ||
| Issuance of Class A Ordinary shares for 2023 Lilly License | | $— | | $7,840 | ||
| Adjustments to redeemable noncontrolling interest from redemption value to carrying value | | $7,017 | | $— | ||
| Share-based equity issuance costs | | $— | | $5,590 | ||
| Settlement of research and development license consideration liability | | $— | | $4,488 | ||
| Transaction costs include in accounts payable and accrued expenses | | $— | | $4,122 | ||
| Reclassification of deferred offering costs to additional paid-in capital | | $— | | $4,015 | ||
| Assumption of public and private placement warrants in connection with Business Combination | | $— | | $3,715 | ||
| Accretion of redeemable noncontrolling interest to redemption value | | $2,337 | | $— | ||
| Reclassification of public warrant liability to equity | | $— | | $2,001 | ||
| Issuance of Call Right to noncontrolling interest | | $— | | $1,541 | ||
| Purchase of property and equipment included in accounts payable and accrued expenses | | $9 | | $— | ||
Zura Bio Limited
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.